Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report)’s stock price traded down 8.2% during trading on Thursday . The company traded as low as $0.7899 and last traded at $0.7899. 3,750 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 11,906 shares. The stock had previously closed at $0.86.
Avacta Group Stock Performance
The business has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $0.87.
Avacta Group Company Profile
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Read More
- Five stocks we like better than Avacta Group
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Your Bank Account Is No Longer Safe
- [Revealed] The $100 Starlink Pre-IPO Jackpot!
- What a Former CIA Agent Knows About the Coming Collapse
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
